pharmaceutical industry

Sourcing from India and China

A Shaky Platform?

Camelot’s Pharma Management Radar

Oxea Expands Alcohol Portfolio to Include 3-Methylbutanol

Chemical manufacturer Oxea announced that it is expanding its portfolio of higher alcohols with 3-methylbutanol (isoamyl alcohol), a versatile intermediate product for the chemical industry.

Olivier Brandicourt Appointed as New CEO of Bayer Healthcare

Ehrfeld Mikrotechnik BTS and Alfa Laval Cooperate in Millireactor Technology

The Epicenter of the U.S. Pharma Industry

New Molecular Entities On The Rise

Catalent to Expand Kentucky Controlled-release Drug Manufacturing Facility

Divisive Elan Boss Martin Faces Ownership Showdown

Teva, Sun Pharma to Pay $2.15 Billion to Settle Pfizer Patent Suit

Ashland to Expand Pharmaceutical Center of Excellence in Delaware

Almac Announces Further Expansion

Former Bristol-Myers Executive Admits to Insider Trading

AstraZeneca Buys U.S. Lung Drug Firm Pearl for up to $1.15 Billion

Sanofi Steps up Diabetes Drive as Rivals Raise the Stakes

FDA Panel Votes to Relax Avandia Restrictions

Ruling Threatens Royalty's Elan Bid Ahead of Key Meeting

After Tech Success, Israel Seeks Life Sciences Growth

SAFC Wins Commercial Licensing of CHOZN Platform in Asia

EU to Fine Lundbeck, Others for Blocking Generic Drugs

CPhI Announces Founding Members of Expert Industry Panel

India's Sun Pharma in Talks to Buy Sweden's Meda for $5-$6 Billion

GSK Bets on Chimp Virus with $321 Million Vaccines Buy

AstraZeneca Buys Heart Firm Omthera for up to $443 Million

Bausch & Lomb's Ista Pleads Guilty Over Kickbacks

Valeant Pharma Near Deal to Acquire Bausch & Lomb

New J&J Anti-depressant Related to "Special K" Party Drug

Forest Labs' Longtime CEO Solomon to Step Down at Year-end

Pfizer Takes its Shot at a Vaccine for Evasive Superbug

Pfizer to Spin Off Zoetis Stake to Shareholders

U.S. Government Taps GlaxoSmithKline for New Antibiotic

AstraZeneca Closes in on Site for New Home in Cambridge

Actavis to Buy Warner Chilcott in $5 Billion Stock Deal

Swedish Drug Maker Recipharm Looks to List or Sell Stake